SCHEMBL18172387

SCHEMBL18172387

CC(CF)(NC(=O)c1cc(-c2ccc(F)cc2)cc(-n2cnnn2)c1)C(F)F

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RY14 Q15391 5/20 0.41
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39
ATM Q13315 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
TSHR P16473 2/20 0.37
LMNA P02545 2/20 0.37
KMT2A Q03164 1/20 0.37
ALDH1A1 P00352 1/20 0.37
GAA P10253 1/20 0.37
TP53 P04637 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
MAPT P10636 1/20 0.36
KLKB1 P03952 1/20 0.35
OPRD1 P41143 1/20 0.35
KCNH2 Q12809 1/20 0.35
KDM4E B2RXH2 1/20 0.35
MAPK1 P28482 1/20 0.35
CTSK P43235 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18172504 0.92 TSHR (0.44) P2RY14NPC1RAB9ATSHRKMT2A
SCHEMBL18172363 0.91 P2RY14 (0.41) P2RY14NPC1RAB9ATSHRKMT2A
SCHEMBL18172458 0.84 P2RY14 (0.42) P2RY14NPC1RAB9AATMNPSR1
SCHEMBL20533433 0.83 P2RY14 (0.44) P2RY14NPC1RAB9AATMNPSR1
SCHEMBL18173623 0.82 P2RX3 (0.37) P2RY14LMNAKMT2ASMN1; SMN2MAPT
SCHEMBL18172442 0.81 P2RX3 (0.39) P2RY14LMNAKMT2AMAPT
SCHEMBL18172352 0.80 P2RY14 (0.41) P2RY14NPC1RAB9AATMNPSR1
SCHEMBL18172460 0.79 P2RY14 (0.62) P2RY14NPC1RAB9ASMN1; SMN2OPRD1
SCHEMBL4321393 0.77 TSHR (0.49) P2RY14NPC1RAB9ATSHRKMT2A
SCHEMBL18172503 0.77 P2RY14 (0.53) P2RY14NPC1RAB9AOPRD1KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3286182-A1 TETRAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF PSYCHIATRIC DISORDERS F. Hoffmann-La Roche AG (CH) 2018-02-28 EP disclosed
WO-2016169902-A1 TETRAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF PSYCHIATRIC DISORDERS F. HOFFMANN-LA ROCHE AG (CH) 2016-10-27 WO disclosed